George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
Not wanting to turn this into a political debate, but Biden is generally perceived as less divisive and more predictable than Trump.
There will be some relief that we can move on from quite a dramatic election.
How paying for all this stimulus will be managed is more of a long term question, short term this market is supported by huge stimulus promises. US government claims that low interest rates and a strong economic recovery, as the population is gradually inoculated, will make the vast emergency spending viable.
A unifying and stable president is being inaugurated tomorrow. A relief to most of the world.
Incoming treasury secretary is urging lawmakers "to act big" on further stimulus, while interest rates are so low.
Johnson and Johnson is very close to releasing its final vaccine trial data and has huge production capacity.
Earnings season is entering its busiest weeks.
Certain US sectors are frothy for sure, but I would not bet on a correction just yet.
Market seems confused since the reaction to the results. The company beat expectations and the price tanked.
Sage are becoming more focused and reinvesting in a core strategy which they believe will add the most value over the long term. I would encourage people to take a closer look at their Full Year results, they were actually quite good.
It is underpriced and may stay that way until the next company update. Not long to go.
I've not come across any analysis on this forum, which reveals any real skeletons. The impact on growth from the pandemic is priced in. Some people are getting frustrated waiting, but I am happy to keep loading up at this level.
I am still buying below 60p, for the reasons I mentioned previously in this thread.
In addition, LIT has had a 25% increase in applications from last year, demonstrating the growth in the demand for funding, due to rising legal disputes, brought on by the pandemic.
MANO claims that they have experienced "zero impact" from COVID-19 and plenty of business to choose from moving forward.
Whereas LIT claims there will be a "minimal" impact on their revenue, as courts had been disrupted during the beginning of the pandemic.
MANO's cases are generally shorter and do not go to court. LIT's cases have on average a longer duration and do need courts, hence some cases will have experienced delays. With these delays some revenue will be deferred, but not lost. The demand for new business is still very strong and they can shift the portfolio to include more insolvency cases + courts are now functioning again, as they have gone virtual.
MANO's update is a positive sign for LIT. LIT's stock offers the best value.
It has been a quiet share. The management was supposed to move to London in March, that has been disrupted obviously.
The company will grow out of its current valuation, with demand for legal disputes likely to grow due to the pandemic's impact. As of August LIT will be the only funder able to operate in Australia, until local competitors can also obtain an AFSL.
LIT's portfolio value and strong track record will get the recognition it deserves, especially if Burford bounces back following their new US listing. Coverage of LIT will not remain so limited, as its market cap increases.
Furthermore, LIT's accounting is different to Burford's, as it uses a cash-based accounting policy, only including revenue on its books when it is received. Muddy Waters claims about Burford are specific to that company, they are not saying that there is a sector-wide issue. Even so, Burford are going for a US listing, which should be a positive catalyst for the sector.
Simon Thompson (Investors Chronicle bargain shares) has commended LIT's performance/prospects and has recommended buying their shares several times at higher prices.
I'm buying at this level for the long term, while shares are mispriced, analyst coverage is limited, the company itself is not making much noise + the market cap and float is small. Markets have also recovered, probably getting ahead of themselves and I'm not finding better entry points for businesses that can still flourish in both worsening or improving economic conditions.
Brexit talks are set to progress now that French & German elections are out of the way. The road to an eventually reasonable deal will likely be a rocky one. Investor sentiment is already negative on UK property and some companies are mispriced regardless of their fundamentals or speciality. Kier is not as risky as Carillion, but its valuation is not attractive. There is nothing apparent which would justify a meaningful upward trend in share price. Losing the support of the dividend this week, combined with the risks related to investor sentiment and the macro environment, the downtrend is set to continue.
The dividend is the bedrock for the investment case and it's not only safe it restricts downside. The dividend has grown annually each year since 1999. Debt ratios will come down as growth capex commitments ease over the next 2 years. The group’s plans have £6bn of capex 2016-20, £5bn of which has already been committed. However, over £3.5bn of this is expected to have already been spent in 2016-18. The yield is not to good to be true, if you pick up some shares now you will receive 7%+ in 2018 from dividends alone.
RCP trades like a low volatility ETF. Downside is limited during market corrections, but you still get a steady continued upside. This is a top pick for when there is blood on the streets, as the Rothschild's would say.
I would hold at 1450p, you could even average down now, if you are in this for the long term. This company is completely different to Carillion and it's debt is manageable. For long term income, it is one of the best large UK non-cyclical companies to be in. If you've got shares at 1450p, next year your div yield will be over 7%+.